Improving antibody affinity by mimicking somatic hypermutation in vitro

Nature Biotechnology

Volumn 17, Issue 6, 1999, Pages 568-572

  Chowdhury, Partha S ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Affinity improvement; Hot spots; Phage display; Single chain antibody

Indexed keywords

IMMUNOTOXIN;

AMINO ACID SEQUENCE; ANTIBODY AFFINITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; DNA LIBRARY; DNA SEQUENCE; GENE MUTATION; MUTAGENESIS; PRIORITY JOURNAL; SOMATIC CELL GENETICS;

ANTIBODY AFFINITY; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CLONING, MOLECULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOTOXINS; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; MUTAGENESIS; TUMOR CELLS, CULTURED;

EID: 0033056238     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/9872     Document Type: Article

References (38)

1. Waldmann, T.A. et al. Radioimmunotherapy of interleukin-2Rα-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood 86, 4063-4075 (1995).
2. Pai, L.H., Wittes, R., Setser, A., Willingham, M.C., and Pastan, I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat. Med. 2, 350-353 (1996).
3. Maloney, D.G. et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 80, 2188-2195 (1997).
4. Osterborg, A. et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 15, 1567-1574 (1997).
5. Baselga, J., Norton, L., Albanell, J., Kim, Y.M. & Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin (M)) enhances the antitumor activity of paclitaxel and doxorubincin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58, 2825-2831 (1998).
6. Goldhirsch, A., Coates, A.S., Castiglione-Gertsch, M. & Gelber, R.D. New treatments for breast cancer: breakthroughs for patient care or just steps in the right direction? Ann. Oncol. 9, 973-976 (1998).
7. Jain, R. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 50, 814s-819s (1990).
8. Clauss, M.A. & Jain, R.K. Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. Cancer Res. 50, 3487-3492 (1990).
9. Yokota, T., Milenic, D.E., Whitlow, M. & Schlom, J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52, 3402-3408 (1992).
10. Adams, G.P. et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-C-erbB2 single chain Fv. Cancer Res. 53, 4026-4034 (1993).
11. Reiter, Y., Brinkmann, U., Lee, B. & Pastan, I. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. Nat. Biotechnol. 14, 1239-1245 (1996).
12. Adams, G.P. et al. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 58, 485-490 (1998).
13. Gram, H. et al. In vitro selection and affinity maturation of antibodies from a naïve combinatorial immunoglobulin library. Proc. Natl. Acad. Sci. USA 89, 3576-3580 (1992).
14. Low, N.M., Holliger, P. & Winter, G. Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain. J. Mol. Biol. 260, 359-368 (1996).
15. de Kruif, J., Boel, E. & Logtenberg, T. Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. J. Mol. Biol. 248, 97-105 (1995).
16. Griffith, A.D. et al. Human anti-self antibodies with high specificity from phage display libraries. EMBO J. 12, 725-734 (1993).
17. Barbas, C.F. et al. Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J. Mol. Biol. 230, 812-823 (1993).
18. Schier, R. et al. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J. Mol. Biol. 255, 28-43 (1996).
19. Yelton, D.E. et al. Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis. J. Immunol. 155, 1994-2004 (1995).
20. Yang, W.-P. et al. CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J. Mol. Biol. 254, 392-403 (1995).
21. Pini, A. et al. Design and use of a phage display library. J. Biol. Chem. 273, 21769-21776 (1998).
22. 3-specific humanized mAb. Proc. Natl. Acad. Sci. USA 95, 6037-6042 (1998).
23. Neuberger, M. S. & Milstein, C. Somatic hypermutation. Curr. Biol. 7, 248-254 (1995).
24. Jolly, C.J. et al. The targeting of somatic hypermutation. Semin. Immunol. 8, 159-168 (1996).
25. Gonzalez-Fernandez, A., Gupta, S.K., Pannell, R., Neuberger, M.S. & Milstein, C. Somatic mutation of immunoglobulin λ chains: a segment of the major intron hypermutates as much as the complementarity-determining regions. Proc. Natl. Acad. Sci. USA 91, 12614-12618 (1994).
26. Golding, G.B., Gearhart, P.J. & Glickman, B.W. Patterns of somatic mutations in immunoglobulin variable genes. Genetics 115, 169-176 (1987).
27. Kolchanov, N.A., Solovyov, V.V. & Rogozin, I.B. Peculiarities of immunoglobulin gene structures as a basis for somatic mutation emergence. FEBS Lett. 214, 87-91 (1987).
28. Rogozin, I.B., Sredneva, N.E. & Kolchanov, N.A. Somatic hypermutagenesis in immunoglobulin genes. III. Somatic mutations in the chicken light chain locus. Biochim. Biophys. Acta 1089, 175-182 (1991).
29. Insel, R.A. & Varade, W.S. Bias in somatic hypermutation of human V-H genes. Int. Immunol. 6, 1437-1443 (1994).
30. Wagner, S.D., Milstein, C. & Meuberger, M.S. Codon bias targets mutation. Nature 376, 732 (1995).
31. Goyenechea, B. & Milstein, C. Modifying the sequence of an immunoglobulin V-gene alters the resulting pattern of hypermutation. Proc. Natl. Acad. Sci. USA 93, 13979-13984 (1996).
32. Chowdhury, P.S., Viner, J., Beers, R. & Pastan, I. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage dis-play and construction of a recombinant immunotoxin with anti-tumor activity. Proc. Natl. Acad. Sci. USA 95, 669-674 (1998).
33. Chang, K. & Pastan, I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl. Acad. Sci. USA 93, 136-140 (1996).
34. Johnson, G., Kabat, E.A. & Wu, T.T. in Weir's handbook of experimental immunology I. Immunochemistry and molecular immunology, 5th edn Ch. 6 (eds Herzenberg, L.A. Weir, W.M., Herzenberg, L.A. & Blackwell, C.) 6.1-6.21 (Blackwell Science, Cambridge, Massachusetts; 1996).
35. Chowdhury, P.S., Vasmatzis, G., Beers, R., Lee, B. & Pastan, I. Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv. J. Mol. Biol. 281, 917-928 (1998).
36. Kunkel, T.A. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc. Natl. Acad. Sci. USA 82, 488-492 (1985).
37. Brinkmann, U. Pai, L.H., FitzGearld, D.J. & Pastan, I. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc. Natl. Acad. Sci. USA 88, 8616-8620 (1991).
38. Chaudhary, V.K. et al. A recombinant immunotoxin consisting of 2 antibody variable domains fused to Pseudomonas exotoxin. Nature 339, 394-397 (1989).